8-K: Helius Medical Technologies Faces Nasdaq Delisting Notice, Plans Appeal

Helius Medical Technologies receives a delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement and intends to appeal the decision.

Summary

• Helius Medical Technologies received a notification from Nasdaq on February 7, 2025, regarding its non-compliance with the minimum bid price requirement, as its common stock price remained below $1.00 for 30 consecutive trading days.
• The company intends to appeal the delisting determination by requesting a hearing before the Nasdaq Hearings Panel.
• The appeal will stay any delisting action pending the outcome of the hearing, and the company's stock will remain listed on Nasdaq during this process.
• Previously, on August 9, 2024, Helius received an initial notice regarding the bid price deficiency and had until February 5, 2025, to regain compliance.
• The company entered into warrant exercise inducement offer letters on January 21, 2025, with certain warrant holders to exercise their existing warrants at a reduced price of $0.751 per share.
• This involved the exercise of warrants for 4,971,110 shares and the issuance of new warrants to purchase up to 6,213,888 shares, subject to stockholder approval.
• Helius expects to hold its 2025 Annual Meeting of Stockholders on April 21, 2025, with a record date of March 12, 2025.
• The deadline for submitting stockholder proposals and director nominations is February 17, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating financial struggles and uncertainty about the company's future on Nasdaq. While the company is taking steps to appeal and raise capital, the overall outlook is concerning.

Positives

• The company is appealing the delisting notice, which will allow its stock to remain listed on Nasdaq at least until the hearing process is complete.
• The warrant exercise inducement offer could bring in additional capital to the company.
• The company is taking steps to regain compliance with Nasdaq listing requirements.

Negatives

• The company received a delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement.
• There is no assurance that the company will ultimately regain compliance and remain listed on Nasdaq.
• The company's stock price has been below $1.00 per share for an extended period.

Risks

• The company may not be successful in its appeal to the Nasdaq Hearings Panel.
• Failure to regain compliance with Nasdaq listing requirements could result in delisting.
• Stockholder approval is required for the warrant exercise inducement, and there is no guarantee that it will be obtained.
• Continued low stock price could negatively impact investor confidence and the company's ability to raise capital.

Future Outlook

The company intends to request a hearing before the Nasdaq Hearings Panel to appeal the delisting determination and present its plan to regain and sustain compliance with the Minimum Bid Price Requirement; however, there is no assurance that the Company will ultimately regain compliance and remain listed on Nasdaq.

Management Comments

• The Company intends to timely request a hearing before the Panel to appeal the determination by the Staff, and to present its plan to regain and sustain compliance with the Minimum Bid Price Requirement.

Industry Context

Many small-cap biotech companies struggle to maintain Nasdaq listing compliance, especially those with limited revenue or those undergoing clinical trials. Delisting can significantly impact investor confidence and access to capital.

Comparison to Industry Standards

• Companies like Helius Medical Technologies often face challenges in maintaining a share price above $1.00, a common requirement for Nasdaq listing.
• Other companies in the biotech sector, such as [hypothetical company A] and [hypothetical company B], have faced similar delisting notices and have pursued strategies such as reverse stock splits or capital raises to regain compliance.
• The success of these strategies varies, and the outcome for Helius will depend on its ability to demonstrate a credible plan for improving its financial performance and stock price.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the value of their investment.
• Employees may experience uncertainty about the company's future.
• The company's ability to raise capital and fund its operations could be affected.

Next Steps

• The company will request a hearing before the Nasdaq Hearings Panel to appeal the delisting determination.
• The company will present its plan to regain and sustain compliance with the Minimum Bid Price Requirement.
• The company will hold its 2025 Annual Meeting of Stockholders on April 21, 2025, to seek stockholder approval for the warrant exercise inducement.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, warrant exercise, inducement, stockholder approval, annual meeting, Helius Medical Technologies, HSDT